Composition for preventing or treating neurodevelopmental disorders and neuroinflammatory diseases, comprising vandetanib as active ingredient
Vandetanib, an oral anticancer drug, addresses the lack of effective treatments for brain developmental disorders and inflammatory diseases by inhibiting microglial and astrogliosis, reducing neuronal damage through suppression of inflammatory responses.
Patent Information
- Application Number
- PCT/KR2026/006115
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2026-05-15
- Filing Date
- 2026-05-15
- Publication Date
- 2026-11-19
AI Technical Summary
There are no effective treatments available for brain developmental disorders and brain inflammatory diseases, which are often triggered by neuroinflammation and exacerbated by the excessive activation of microglia and astrocytes, leading to neuronal damage and death.
The use of vandetanib, an oral anticancer drug, to inhibit the inflammatory response by reducing the activity of microglia and astrocytes, thereby preventing and treating brain developmental disorders and brain inflammatory diseases.
Vandetanib effectively inhibits the production of pro-inflammatory cytokines, reduces microglial and astrogliosis, and protects neurons from damage by suppressing the activation of microglia and astrocytes, offering a new therapeutic approach for these conditions.
Smart Images

Figure KR2026006115_19112026_PF_FP_ABST
Abstract
Description
A composition for the prevention or treatment of brain developmental disorders and brain inflammatory diseases containing vandetanib as an active ingredient
[0001] The present invention was carried out under the support of the Ministry of Science and ICT under project unique number 2025006800 and project number H0301-24-1001, the research management agency for the above project is the Korea Information and Communication Industry Promotion Agency, the research project name is “Demonstration Support for AI-based Digital Medical Devices for Brain Developmental Disorders”, the research task name is “Demonstration Support for AI-based Digital Medical Devices for Brain Developmental Disorders”, the lead institution is the Korea Brain Research Institute, and the research period is April 1, 2024 to December 31, 2026.
[0002] The present invention was carried out under the support of the Ministry of Science and ICT under project number 2710094328 and project number 25-BR-02-04, with the research management agency for the above project being the Korea Brain Research Institute, the research project name being “Support for Korea Brain Research Institute Research Operation Expenses”, the research project name being “Discovery of Novel Molecular Targets Related to Neurodegenerative Diseases and Derivation of Therapeutic Candidates”, the lead institution being the Korea Brain Research Institute, and the research period being January 1, 2025 to December 31, 2025.
[0003] The present invention was carried out under the support of the Ministry of Science and ICT under project number 2710105485 and project number 20260124, with the research management agency for the said project being the National Research Foundation, the research project name being “Individual Basic Research”, the research project name being “Development of Source Technology for Integrated Non-Invasive Treatment of FC-PNM / G-CNVS for Cognitive Function Modulation Based on Plc-xd Family Targets”, the lead institution being the Korea Brain Research Institute, and the research period being March 1, 2026 to February 28, 2027.
[0004] The present invention relates to a composition for the prevention or treatment of brain developmental disorders and brain inflammatory diseases comprising vandetanib as an active ingredient.
[0005] Brain developmental disorder refers to a condition in which intellectual and motor developmental disorders, language developmental disorders, special sensory function disorders such as visual and auditory impairments, and other learning disabilities occur due to congenital or developmental brain damage. If the brain fails to grow and mature properly according to developmental stages, individuals with such disorders may suffer from lifelong intellectual, learning, behavioral, and motor disabilities.
[0006] These brain developmental disorders arise from various causes, including congenital brain developmental abnormalities due to chromosomal abnormalities, as well as biological factors such as prematurity, perinatal complications, various metabolic disorders occurring after birth, infection, hemorrhage, and hypoxia. They are also associated with various socioeconomic environmental factors related to parents, such as parental neglect or isolation, drug addiction, and maternal alcohol consumption.
[0007] Furthermore, according to recently reported research findings, the occurrence of brain inflammation can induce epigenetic changes in brain regions associated with higher cognitive functions and has been reported to be potentially involved in the development of various neuropsychiatric disorders. Additionally, studies have reported that severe inflammation occurring during infancy interferes with brain cell development, increasing the risk of developing brain developmental disorders such as autism spectrum disorder and schizophrenia.
[0008] However, the development of treatments capable of effectively preventing, improving, and treating brain developmental disorders is still lacking.
[0009] Neuroinflammation is a type of immune response of the nervous system and is reported to be closely associated with the pathogenesis of many neurodegenerative diseases, including Alzheimer's, Parkinson's, and multiple sclerosis, as well as brain developmental disorders such as Attention Deficit Hyperactivity Disorder (ADHD), schizophrenia, bipolar disorder, and autism spectrum disorder (ASD). The neuroinflammatory response involves the activation of innate immune cells (microglia), the release of inflammatory mediators such as nitric oxide (NO), cytokines, and chemokines, and macrophage infiltration, which induce neuronal death.
[0010] Furthermore, the activation of microglia and astrocytes is known to be involved in the onset and progression of various neurodegenerative diseases, including brain inflammation. Microglia are immune cells residing in the central nervous system (CNS) that are activated by external stimuli to induce immune and inflammatory responses. As cells that perform primary immune functions in the CNS, microglia maintain a shape of long, slender branches and thin cell bodies; however, when toxins are introduced from the outside or generated internally, they transform into an activated form with short, thick branches and thick cell bodies to protect nerve cells from these toxins.
[0011] However, when microglia are activated by substances such as lipopolysaccharide (LPS), a bacterial endotoxin, interferon-γ, beta-amyloid, or gangliosides, unlike normal microglia, they actively phagocytose, proliferate, and produce inflammatory mediators by expressing genes such as cytokines (TNF-α, IL-1β, IL-6), chemokines, iNOS (inducible nitric oxide synthase), and COX-2 (cyclooxygenase-2). While this activation of microglia has the aspect of removing damaged cells and protecting neurons from invading bacteria or viruses, nitric oxide (NO) produced by iNOS, prostaglandins produced by COX-2, and TNF-α also exhibit toxicity to neurons; consequently, the activation of microglia exacerbates neuronal damage. Therefore, appropriate inhibition of microglia activation can be another method to treat various neurodegenerative diseases, including brain inflammation.
[0012] Furthermore, astrocytes play a crucial role not only in the process of brain development but also in maintaining normal brain activity. It has been revealed that astrocytes in the brain assist neuronal activity by appropriately removing neurotransmitters secreted by neurons or regulating ion concentrations within the brain; additionally, they have been shown to play a decisive role in the differentiation of neural stem cells into neurons.
[0013] However, when the brain is injured, astrocytes proliferate rapidly, swelling occurs, and they become activated into reactive astrocytes, such as in astrogliosis. These reactive astrocytes are observed in AIDS-induced dementia, brain injury, ischemic brain disease, and Alzheimer's disease. Therefore, continuous activation of astrocytes eventually leads to neuronal death. Thus, appropriately inhibiting the activation of astrocytes can also be another method to treat various degenerative brain diseases, including brain inflammatory diseases.
[0014] Meanwhile, vandetanib is an oral anticancer drug prescribed for the treatment of unresectable locally advanced or metastatic medullary thyroid cancer. It is particularly recommended as a first-line treatment for advanced medullary thyroid cancer and is known as a drug used for severe, life-threatening conditions. Vandetanib primarily acts as a kinase inhibitor of vascular endothelial growth factor receptor, epidermal growth factor receptor, and RET-tyrosine kinase.
[0015] However, there are no known studies to date indicating that the drug vandetanib can prevent or treat brain developmental disorders and brain inflammatory diseases by regulating the brain's inflammatory response.
[0016] Accordingly, the inventors have completed the present invention by identifying that vandetanib, an anticancer drug prescribed as a conventional anticancer drug, can control the inflammatory response of neurons, inhibit the activity of microglia and astrocytes, and has neuroprotective activity, and can ultimately be used as a new therapeutic agent for the prevention, improvement, and treatment of brain developmental disorders and brain inflammatory diseases.
[0017] Therefore, the object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of brain developmental disorders or brain inflammatory diseases comprising vandetanib or a pharmaceutically acceptable salt thereof as an active ingredient.
[0018] Another objective of the present invention is to provide a food composition for the prevention or improvement of brain developmental disorders or brain inflammatory diseases, comprising vandetanib or a salt thereof as an active ingredient.
[0019] To achieve the above objective, the present invention provides a pharmaceutical composition for the prevention or treatment of brain developmental disorders or brain inflammatory diseases, comprising vandetanib or a pharmaceutically acceptable salt thereof as an active ingredient.
[0020] In one embodiment of the present invention, the composition may have the effect of inhibiting the production of pro-inflammatory cytokines; inhibiting the expression of NLRP3 and SOD2; inhibiting the activity of JNK and NK-κB signaling pathways; or inhibiting the activity of microglia or astrocytes.
[0021] In one embodiment of the present invention, the composition may inhibit apoptosis of nerve cells.
[0022] In one embodiment of the present invention, the inhibition of apoptosis may be the inhibition of pyroptosis.
[0023] In one embodiment of the present invention, the composition may inhibit an inflammatory response within a neuronal cell.
[0024] In one embodiment of the present invention, the inflammation may be induced by LPS (Lipopolysaccharide).
[0025] In one embodiment of the present invention, the pro-inflammatory cytokine may be IL-1β, IL-6, COX-2, or TNF-α.
[0026] In one embodiment of the present invention, the brain developmental disorder may be selected from the group consisting of attention deficit hyperactivity disorder (ADHD), schizophrenia, bipolar disorder, and autism spectrum disorder (ASD).
[0027] In one embodiment of the present invention, the brain inflammatory disease may be selected from the group consisting of multiple sclerosis, stroke, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, Creutzfeldt-Jakob disease, post-traumatic stress disorder, depression, schizophrenia, and amyotrophic lateral sclerosis.
[0028] In addition, the present invention provides a food composition for the prevention or improvement of brain developmental disorders or brain inflammatory diseases, comprising vandetanib or a salt thereof as an active ingredient.
[0029] In one embodiment of the present invention, the composition may have the effect of inhibiting the production of pro-inflammatory cytokines; inhibiting the expression of NLRP3 and SOD2; inhibiting the activity of JNK and NK-κB signaling pathways; or inhibiting the activity of microglia or astrocytes.
[0030] In one embodiment of the present invention, the composition may inhibit pyroptosis of nerve cells.
[0031] In one embodiment of the present invention, the composition may inhibit an inflammatory response induced by LPS (Lipopolysaccharide).
[0032] In one embodiment of the present invention, the brain developmental disorder may be selected from the group consisting of attention deficit hyperactivity disorder (ADHD), schizophrenia, bipolar disorder, and autism spectrum disorder (ASD).
[0033] In one embodiment of the present invention, the brain inflammatory disease may be selected from the group consisting of multiple sclerosis, stroke, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, Creutzfeldt-Jakob disease, post-traumatic stress disorder, depression, schizophrenia, and amyotrophic lateral sclerosis.
[0034] A composition containing vantetanib according to the present invention can inhibit the production of pro-inflammatory cytokines, inhibit the expression of NLRP3 and SOD2, inhibit the activity of JNK and NK-κB signaling pathways, and inhibit the activity of microglia or astrocytes, and has neuroprotective activity by inhibiting apoptosis of neurons, so it can be usefully used as a new therapeutic agent to ultimately prevent, improve, or treat brain developmental disorders and brain inflammatory diseases.
[0035] Figure 1 is a diagram showing the chemical formula structure of bandetanib.
[0036] Figure 2 is a graph showing the results of evaluating the cytotoxicity of vandetanib in BV2 microglia using an MTT assay.
[0037] Figure 3 is a graph showing the expression level of COX-2 mRNA measured after treating BV2 microglia with LPS alone, or with vandetanib 1 μM and LPS or vandetanib 5 μM and LPS.
[0038] Figure 4 is a graph showing the expression levels of Il-1β mRNA measured after treating BV2 microglia with LPS alone, or with vandetanib 1 μM and LPS or vandetanib 5 μM and LPS.
[0039] Figure 5 is a graph showing the expression level of TNF-α mRNA measured after administering LPS alone to BV2 microglia, or after treating with vandetanib 1 μM and LPS or vandetanib 5 μM and LPS.
[0040] Figure 6 is a graph showing the expression level of IL-6 mRNA measured after treating BV2 microglia with LPS alone, or with vandetanib 1 μM and LPS or vandetanib 5 μM and LPS.
[0041] Figure 7 is a graph showing the expression level of COX-2 mRNA measured after treating primary microglia with LPS alone or with vandetanib 5 μM and LPS.
[0042] Figure 8 is a graph showing the expression level of Il-1β mRNA measured after treating primary microglia with LPS alone or with vandetanib 5 μM and LPS.
[0043] Figure 9 is a graph showing the expression level of TNF-α mRNA measured after treating primary microglia with LPS alone or with vandetanib 5 μM and LPS.
[0044] Figure 10 is a graph showing the expression level of IL-6 mRNA measured after administering LPS alone to primary microglia or treating them with vandetanib 5 μM and LPS.
[0045] Figure 11 is a graph showing the level of VEGFR2 mRNA expression in the brain measured after administering LPS alone to wild-type mice, or after sequentially administering LPS after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0046] Figure 12 is a graph showing the brain EGFR mRNA expression levels measured after administering LPS alone to wild-type mice, or after sequentially administering LPS after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0047] Figure 13 shows the results of Iba-1 fluorescence staining of the cortex in wild-type mice after administering LPS alone or after sequentially administering LPS after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0048] Figure 14 shows the results of Iba-1 fluorescence staining of the hippocampus in wild-type mice after administering LPS alone or after sequentially administering LPS after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0049] Figure 15 is a graph showing the Iba-1 fluorescence intensity in the cortex and hippocampus after administering LPS alone to wild-type mice, or after sequentially administering LPS after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0050] Figure 16 is a graph showing the area of Iba-1 positive areas in the cortex and hippocampus after administering LPS alone to wild-type mice, or after sequentially administering LPS after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0051] Figure 17 is a graph showing the number of Iba-1 positive cells in the cortex and hippocampus after administering LPS alone to wild-type mice, or after injecting vandetanib (5 mg / kg) or vehicle for 14 days followed by sequential administration of LPS.
[0052] Figure 18 is a graph comparing the expression levels of COX-2 mRNA after treating primary astrocytes with LPS alone or with vandetanib 5 μM and LPS.
[0053] Figure 19 is a graph comparing the expression levels of IL-1β mRNA after treating primary astrocytes with LPS alone or with vandetanib 5 μM and LPS.
[0054] Figure 20 is a graph comparing the expression levels of TNF-α mRNA after treating primary astrocytes with LPS alone or with vandetanib 5 μM and LPS.
[0055] Figure 21 is a graph comparing the expression levels of IL-6 mRNA after treating primary astrocytes with LPS alone or with vandetanib 5 μM and LPS.
[0056] Figure 22 is a diagram showing the results of GFAP fluorescence staining of the cortex in wild-type mice after administering LPS alone or after sequentially administering LPS after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0057] Figure 23 is a diagram showing the GFAP fluorescence staining results of the hippocampus after administering LPS alone to wild-type mice, or after sequentially administering LPS after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0058] Figure 24 is a graph showing the GFAP fluorescence intensity in the cortex and hippocampus after administering LPS alone to wild-type mice, or after sequentially administering LPS after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0059] Figure 25 is a graph showing the GFAP-positive area of the cortex and hippocampus measured after administering LPS alone to wild-type mice, or after injecting vandetanib (5 mg / kg) or vehicle for 14 days followed by sequential administration of LPS.
[0060] Figure 26 is a graph showing the number of GFAP-positive cells in the cortex and hippocampus after administering LPS alone to wild-type mice, or after sequentially administering LPS after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0061] Figure 27 is a graph comparing the expression levels of Il-1β mRNA in the cortex and hippocampus of wild-type mice after administering LPS alone or after sequentially administering LPS following injection of vandetanib (5 mg / kg) or vehicle for 14 days.
[0062] Figure 28 is a graph comparing the expression levels of TNF-α mRNA in the cortex and hippocampus after administering LPS alone to wild-type mice, or after sequentially administering LPS following injection of vandetanib (5 mg / kg) or vehicle for 14 days.
[0063] Figure 29 is a graph comparing the expression levels of COX-2 mRNA in the cortex and hippocampus of wild-type mice after administering LPS alone or after sequentially administering LPS following injection of vandetanib (5 mg / kg) or vehicle for 14 days.
[0064] Figure 30 shows the results of IL-1β immunofluorescence staining of the cortex in wild-type mice after administering LPS alone or after sequentially administering LPS after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0065] Figure 31 shows the results of IL-1β immunofluorescence staining in the hippocampus after administering LPS alone to wild-type mice, or after sequentially administering LPS after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0066] Figure 32 is a graph showing the comparison of IL-1β fluorescence intensity in the cortex and hippocampus after administering LPS alone to wild-type mice, or after sequentially administering LPS after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0067] Figure 33 shows the results of TNF-α immunofluorescence staining of the cortex in wild-type mice after administering LPS alone or after sequentially administering LPS after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0068] Fig. 34 shows the results of TNF-α immunofluorescence staining in the hippocampus after administering LPS alone to wild-type mice, or after injecting vandetanib (5 mg / kg) or vehicle for 14 days followed by sequential administration of LPS.
[0069] Figure 35 is a graph showing the comparison of TNF-α fluorescence intensity in the cortex and hippocampus after administering LPS alone to wild-type mice, or after sequentially administering LPS after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0070] Figure 36 shows the results of COX-2 immunofluorescence staining of the cortex in wild-type mice after administering LPS alone or after sequentially administering LPS after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0071] Figure 37 shows the results of COX-2 immunofluorescence staining of the hippocampus in wild-type mice after administering LPS alone or after sequentially administering LPS after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0072] Figure 38 is a graph showing the comparison of COX-2 fluorescence intensity in the cortex and hippocampus after administering LPS alone to wild-type mice, or after sequentially administering LPS after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0073] Figure 39 is a graph showing the expression levels of CXCL10 mRNA in the cortex and hippocampus after administering LPS alone to wild-type mice, or after sequentially administering LPS following injection of vandetanib (5 mg / kg) or vehicle for 14 days.
[0074] Figure 40 is a graph showing the expression levels of CD44 mRNA in the cortex and hippocampus after administering LPS alone to wild-type mice, or after sequentially administering LPS after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0075] Figure 41 is a graph showing the expression levels of TSPO mRNA in the cortex and hippocampus after administering LPS alone to wild-type mice, or after sequentially administering LPS following injection of vandetanib (5 mg / kg) or vehicle for 14 days.
[0076] Figure 42 is a graph showing the expression levels of GBP2 mRNA in the cortex and hippocampus after administering LPS alone to wild-type mice, or after sequentially administering LPS after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0077] Figure 43 is a graph showing the expression levels of GPNMB mRNA in the cortex and hippocampus after administering LPS alone to wild-type mice, or after sequentially administering LPS following injection of vandetanib (5 mg / kg) or vehicle for 14 days.
[0078] Figure 44 is a graph showing the expression levels of CR3 mRNA in the cortex and hippocampus after administering LPS alone to wild-type mice, or after sequentially administering LPS after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0079] Figure 45 shows the p-JNK and JNK protein expression in BV2 microglia after treatment with LPS alone or with vandetanib 5 μM and LPS, confirmed by Westin blot.
[0080] Figure 46 is a graph showing the change in p-JNK protein expression levels after treatment with LPS alone or with vandetanib 5 μM and LPS in BV2 microglia.
[0081] Figure 47 is a graph showing the change in JNK protein expression levels after treatment with LPS alone or with vandetanib 5 μM and LPS in BV2 microglia.
[0082] Figure 48 shows the p-JNK and JNK protein expression in primary astrocytes after treatment with LPS alone or 5 μM of vandetanib, confirmed by Westin blot.
[0083] Figure 49 is a graph showing the change in p-JNK protein expression levels after treatment with LPS alone or with vandetanib 5 μM and LPS in primary astrocytes.
[0084] Figure 50 is a graph showing the change in JNK protein expression levels after treatment with LPS alone or with vandetanib 5 μM and LPS in primary astrocytes.
[0085] Figure 51 is a diagram showing the p-P38 and P38 protein expression in primary astrocytes after treatment with LPS alone or with vandetanib 5 μM and LPS, confirmed by Westin blot.
[0086] Figure 52 is a graph showing the change in p-P38 protein expression levels after treatment with LPS alone or with vandetanib 5 μM and LPS in primary astrocytes.
[0087] Figure 53 is a graph showing the change in P38 protein expression levels after treatment with LPS alone or with vandetanib 5 μM and LPS in primary astrocytes.
[0088] Figure 54 is a diagram showing the expression levels of pc-Jun and c-Jun proteins in primary astrocytes after treatment with LPS alone or with vandetanib 5 μM and LPS, confirmed by Western blot.
[0089] Figure 55 is a graph showing the phosphorylation level of pc-Jun protein after treatment of primary astrocytes with LPS alone or with vandetanib 5 μM and LPS.
[0090] Figure 56 is a diagram showing the expression levels of p-STAT3 and STAT3 proteins in primary astrocytes after treatment with LPS alone or with vandetanib 5 μM and LPS, confirmed by Western blot.
[0091] Figure 57 is a graph showing the phosphorylation levels of p-STAT3 and STAT3 proteins after treatment of primary astrocytes with LPS alone or with vandetanib 5 μM and LPS.
[0092] Figure 58 is a diagram showing the levels of pc-Jun and c-Jun protein expression in the cortex of wild-type mice after administering LPS alone or sequentially administering LPS after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0093] Figure 59 is a graph comparing the phosphorylation level of pc-Jun protein in the cortex after administering LPS alone to wild-type mice, or after injecting vandetanib (5 mg / kg) or vehicle for 14 days followed by sequential administration of LPS.
[0094] Figure 60 is a graph comparing the phosphorylation level of c-Jun protein in the cortex after administering LPS alone to wild-type mice, or after sequentially administering LPS after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0095] Figure 61 is a diagram showing the levels of pc-Jun and c-Jun protein expression in the hippocampus of wild-type mice after administering LPS alone or sequentially administering LPS after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0096] Figure 62 is a graph comparing the phosphorylation level of pc-Jun protein in the hippocampus after administering LPS alone to wild-type mice, or after sequentially administering LPS after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0097] Figure 63 is a graph comparing the phosphorylation level of c-Jun protein in the hippocampus after administering LPS alone to wild-type mice, or after injecting vandetanib (5 mg / kg) or vehicle for 14 days followed by sequential administration of LPS.
[0098] Figure 64 is a diagram showing the levels of p-STAT3 and STAT3 protein expression in the cortex of wild-type mice after administering LPS alone or sequentially administering LPS after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0099] Figure 65 is a graph comparing the phosphorylation level of p-STAT3 protein in the cortex after administering LPS alone to wild-type mice, or after sequentially administering LPS after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0100] Figure 66 is a graph comparing the phosphorylation of STAT3 protein in the cortex after administering LPS alone to wild-type mice, or after injecting vandetanib (5 mg / kg) or vehicle for 14 days followed by sequential administration of LPS.
[0101] Figure 67 is a diagram showing the levels of p-STAT3 and STAT3 protein expression in the hippocampus of wild-type mice after administering LPS alone or sequentially administering LPS after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0102] Figure 68 is a graph comparing the phosphorylation level of p-STAT3 protein in the hippocampus after administering LPS alone to wild-type mice, or after injecting vandetanib (5 mg / kg) or vehicle for 14 days followed by sequential administration of LPS.
[0103] Figure 69 is a graph comparing the phosphorylation level of STAT3 protein in the hippocampus after administering LPS alone to wild-type mice, or after injecting vandetanib (5 mg / kg) or vehicle for 14 days followed by sequential administration of LPS.
[0104] Figure 70 is a graph showing the change in expression levels of NLRP6 mRNA in the cortex and hippocampus when LPS was administered alone to wild-type mice, or when LPS was administered sequentially after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0105] Figure 71 is a graph showing the change in the expression levels of ASC mRNA in the cortex and hippocampus when LPS was administered alone to wild-type mice, or when LPS was administered sequentially after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0106] Figure 72 is a graph showing the change in expression levels of HMGB1 mRNA in the cortex and hippocampus when LPS was administered alone to wild-type mice, or when LPS was administered sequentially after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0107] Figure 73 is a graph showing the change in expression levels of CASPASE-1 mRNA in the cortex and hippocampus when LPS was administered alone to wild-type mice, or when LPS was administered sequentially after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0108] Figure 74 is a graph showing the change in expression levels of IL-18 mRNA in the cortex and hippocampus when LPS was administered alone to wild-type mice, or when LPS was administered sequentially after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0109] Figure 75 is a graph showing the change in expression levels of GSDMD mRNA in the cortex and hippocampus when LPS was administered alone to wild-type mice, or when LPS was administered sequentially after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0110] Figure 76 is a graph showing the changes in NLRP3 mRNA expression levels in the cortex and hippocampus when LPS was administered alone to wild-type mice, or when LPS was administered sequentially after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0111] Figure 77 is a graph showing the changes in Pro-IL-1β mRNA expression levels in the cortex and hippocampus when LPS was administered alone to wild-type mice, or when LPS was administered sequentially after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0112] Figure 78 is a graph showing the comparison of NLRP3 mRNA expression levels after treating BV2 microglia with LPS alone, or with vandetanib 1 μM and LPS or vandetanib 5 μM and LPS.
[0113] Figure 79 is a diagram showing the level of NLRP3 protein expression in BV2 microglia after treatment with LPS alone or with vandetanib 5 μM and LPS, confirmed by Western blot.
[0114] Figure 80 is a graph showing the comparison of NLRP3 protein expression levels after treating BV2 microglia with LPS alone or with vandetanib 5 μM and LPS.
[0115] Figure 81 is a graph comparing the mRNA expression levels of NLRP3 and Pro-IL-1β when primary microglia were treated with LPS alone or with vandetanib 5 μM and LPS.
[0116] Figure 82 is a graph comparing the mRNA expression levels of NLRP3 and Pro-IL-1β when primary astrocytes were treated with LPS alone or with vandetanib 5 μM and LPS.
[0117] Figure 83 is a graph showing the expression of Nlrp3 mRNA after inhibiting Nlrp3 expression in BV2 microglia using siRNA NLRP3 and then treating with LPS alone or with vandetanib 5 μM and LPS.
[0118] Figure 84 is a graph showing the change in COX-2 mRNA expression levels after inhibiting Nlrp3 expression in BV2 microglia using siRNA NLRP3 and then treating with LPS alone or with vandetanib 5 μM and LPS.
[0119] Figure 85 is a graph showing the change in IL-1β mRNA expression levels in BV2 microglia after transfection with control siRNA and NLRP3 siRNA, followed by treatment with LPS alone or with vandetanib 5 μM and LPS.
[0120] Figure 86 is a graph showing the change in IL-6 mRNA expression levels after transfection with control siRNA and NLRP3 siRNA in BV2 microglia, followed by treatment with LPS alone or with vandetanib 5 μM and LPS.
[0121] Figure 87 is a graph showing the change in TNF-α mRNA expression levels after transfection with control siRNA and NLRP3 siRNA in BV2 microglia, followed by treatment with LPS alone or with vandetanib 5 μM and LPS.
[0122] Figure 88 is a graph showing the change in the expression level of SOD2 mRNA after treating BV2 microglia with LPS alone, or with vandetanib 1 μM and LPS or vandetanib 5 μM and LPS.
[0123] Figure 89 is a graph showing the change in SOD2 mRNA expression levels in the cortex and hippocampus when LPS was administered alone to wild-type mice, or when LPS was administered sequentially after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0124] Figure 90 is an immunofluorescence staining result showing the change in the expression level of SOD2 protein in the cortex when LPS was administered alone to wild-type mice, or when LPS was administered sequentially after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0125] Figure 91 is a graph showing the change in the expression level of SOD2 protein in the cortex when LPS was administered alone to wild-type mice, or when LPS was administered sequentially after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0126] Figure 92 is an immunofluorescence staining result diagram showing the change in SOD2 protein expression levels in hippocampal CA1 when LPS was administered alone to wild-type mice, or when LPS was administered sequentially after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0127] Figure 93 is a graph showing the change in SOD2 protein expression levels in hippocampal CA1 when LPS was administered alone to wild-type mice, or when LPS was administered sequentially after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0128] Figure 94 is an immunofluorescence staining result diagram showing the change in SOD2 protein expression levels in hippocampal DGs when LPS was administered alone to wild-type mice, or when LPS was administered sequentially after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0129] Figure 95 is a graph showing the change in SOD2 protein expression levels in hippocampal DGs when LPS was administered alone to wild-type mice, or when LPS was administered sequentially after injecting vandetanib (5 mg / kg) or vehicle for 14 days.
[0130] Figure 96 is a graph showing the change in the expression level of SOD2 mRNA when BV2 microglia were transfected with control siRNA and SOD2 siRNA, and then treated with LPS alone or with vandetanib 5 μM and LPS.
[0131] Figure 97 is a graph showing the change in COX-2 mRNA expression levels when BV2 microglia were transfected with control siRNA and SOD2 siRNA, and then treated with LPS alone or with vandetanib 5 μM and LPS.
[0132] Figure 98 is a graph showing the change in IL-1β mRNA expression levels when BV2 microglia were transfected with control siRNA and SOD2 siRNA, and then treated with LPS alone or with vandetanib 5 μM and LPS.
[0133] Figure 99 is a graph comparing the expression levels of Gpr139 mRNA in the hippocampus, habenula, and medial prefrontal cortex of 7-month-old Gpr139+ / + mice and Gpr139- / - mice.
[0134] Figure 100 is a graph showing the distance traveled in the open arm when an elevated plus maze test to measure hyperactivity was performed on 7-month-old Gpr139+ / + mice and Gpr139- / - mice after administering vandetanib (5 mg / kg) or vehicle daily for 14 days.
[0135] Figure 101 is a graph showing the distance traveled in the closed arm when an elevated plus maze test to measure hyperactivity was performed on 7-month-old Gpr139+ / + mice and Gpr139- / - mice after administering vandetanib (5 mg / kg) or vehicle daily for 14 days.
[0136] Figure 102 is a graph showing the results of searching for the same object (training) and preference for the novel object (test) when a novel object recognition test, a cognitive behavioral test capable of measuring attention deficit, was performed on 7-month-old Gpr139+ / + mice and Gpr139- / - mice after administering vandetanib (5 mg / kg) or vehicle daily for 14 days.
[0137] Figure 103 is a graph showing the results of measuring sociality through the analysis of search time on an empty grid and a peer when a 3-chamber test, a behavioral test capable of measuring sociality and attention deficit, was performed on Gpr139+ / + mice and Gpr139- / - mice after administering vandetanib (5 mg / kg) or vehicle daily for 14 days.
[0138] Figure 104 is a graph showing the change in sociality index when a 3-chamber test was performed after administering vandetanib (5 mg / kg) or vehicle to Gpr139+ / + mice and Gpr139- / - mice daily for 14 days.
[0139] Figure 105 is a graph showing the results of measuring social recognition memory (attention deficit) through the analysis of search time for familiar and novel individuals when a 3-chamber test, a behavioral test capable of measuring sociality and attention deficit, was performed on Gpr139+ / + mice and Gpr139- / - mice after administering vandetanib (5 mg / kg) or vehicle daily for 14 days.
[0140] Figure 106 is a graph showing the change in social cognitive index when a 3-chamber test was performed after administering vandetanib (5 mg / kg) or vehicle to Gpr139+ / + mice and Gpr139- / - mice daily for 14 days.
[0141] A pharmaceutical composition for the prevention or treatment of brain developmental disorders or brain inflammatory diseases, comprising vandetanib or a pharmaceutically acceptable salt thereof as an active ingredient.
[0142] The present invention relates to a composition for the prevention or treatment of brain developmental disorders or brain inflammatory diseases comprising vandetanib or a pharmaceutically acceptable salt thereof as an active ingredient, and the present invention first identified that the drug vandetanib can be used as a treatment for brain developmental disorders or brain inflammatory diseases.
[0143] According to reported research findings regarding brain diseases, the induction of inflammation in neurons is associated with the onset of brain developmental disorders. However, there is currently no effective treatment available to treat brain developmental disorders.
[0144] Accordingly, while researching to develop a new therapeutic agent capable of treating brain developmental disorders, the inventors confirmed that vandetanib, a drug prescribed as a conventional anticancer agent, has an excellent effect in inhibiting the induction of inflammation in nerve cells, thereby identifying that vandetanib can be used as a therapeutic agent for brain developmental disorders or brain inflammatory diseases.
[0145] In this regard, according to one embodiment of the present invention, it was confirmed that vandetanib of the present invention inhibits LPS-induced inflammatory responses in microglia and astrocytes, and specifically, it was confirmed that it can significantly inhibit the expression levels of pro-inflammatory cytokines such as IL-1β, IL-6, TNF-α, or COX-2 mRNA.
[0146] In addition, according to another embodiment of the present invention, it was confirmed that vandetanib inhibits the activity of microglia or astrocytes caused by LPS administration, thereby inhibiting damage to neurons caused by activated microglia or activated astrocytes. Specifically, after administering vandetanib daily to wild-type mice for 14 days, microgliosis and astrogliosis were induced by administering LPS, a neuroinflammatory inducer. As a result, it was confirmed that in the group administered vandetanib of the present invention, microgliosis and astrogliosis induced by LPS were improved compared to the vehicle administration group.
[0147] Therefore, these results indicate that vandetanib of the present invention can effectively inhibit the activation of microglia and astrocytes induced by LPS.
[0148] Microglial cells are important effector cells that regulate immune responses within the central nervous system (CNS). Their activation plays a crucial role in maintaining CNS homeostasis by removing foreign substances, such as drugs or toxins, and secreting nerve growth factors. However, exposure to harmful stressors—such as signals from damaged neurons, the accumulation of abnormally modified proteins due to external stimuli, or the invasion of pathogens—can lead to excessive microglia activation. This excessive increase in activity can cause neuronal damage, potentially resulting in brain diseases such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, cerebral infarction, and brain developmental disorders. Therefore, the excessive activation of microglial cells could serve as a new therapeutic approach for brain diseases.
[0149] Furthermore, unlike normal microglia, overly activated microglia produce inflammatory mediators by overexpressing genes such as cytokines like TNF-α, IL-1β, and IL-6, chemokines, iNOS (inducible nitric oxide synthase), and COX-2 (cyclooxygenase-2). While the activation of microglia has the effect of removing damaged cells and protecting neurons from invading bacteria or viruses, nitric oxide (NO) produced by iNOS, prostaglandins produced by COX-2, and TNF-α are toxic to neurons; consequently, the activation of microglia exacerbates neuronal damage and acts as a cause of brain disease.
[0150] Furthermore, astrocytes are also known to play a crucial role in maintaining normal brain activity, specifically in the formation of synapses, regulation of synapse numbers, synaptic function, and the differentiation of neural stem cells into neurons. However, if these astrocytes become excessively reactive—that is, if they remain in a state of excessive activation—they can cause neuronal death and induce the death of neighboring neurons, thereby acting as a cause of brain diseases. Therefore, inhibiting excessive astrocyte activation could also serve as a new treatment method for brain diseases.
[0151] The substances causing excessive activation of microglia and astrocytes may include bacterial endotoxins such as lipopolysaccharide (LPS), interferon-γ, beta-amyloid, and gangliosides, but in one embodiment of the present invention, it may preferably be lipopolysaccharide (LPS).
[0152] In addition, as the inventors confirmed through in vitro and in vivo experiments that vandetanib of the present invention has the effect of suppressing neuroinflammation, that is, brain inflammatory response, they conducted experiments to determine specifically by what mechanism the suppression of brain inflammation by vandetanib is achieved.
[0153] As a result, it was confirmed that vandetanib of the present invention can suppress LPS-mediated neuroinflammatory responses by inhibiting the activity of LPS-induced NLRP3 / SOD2 and inhibiting the activity of the JNK / NK-κB signaling pathway.
[0154] NLRP3 (NOD-like receptor protein 3; NLRP3) is a protein-coding gene that belongs to the family of nucleotide-binding and oligomerization domain (NOD)-like receptors (NLR). NLRP3 codes for a protein containing a pyrine domain, a nucleotide-binding site domain (NBD), and a leucine-rich repeat (LRR) motif. NLRP3 responds to sterile inflammatory danger signals by interacting with adapter proteins, apoptosis-associated speck-like protein (ASC), and pro-caspase-1 to form the NLRP3 inflasmasome, and activation of the NLRP3 inflasmasome leads to the release of inflammatory cytokines IL-1β and IL-18, which can cause a number of diseases.
[0155] Activated cytokines derived from NLRP3 inflammasome activation are important drivers of inflammation and interact with other cytokine pathways to shape immune responses to infection and injury. For example, IL-1β signaling induces the secretion of pro-inflammatory cytokines IL-6 and TNF. IL-1β and IL-18 synergize with IL-23 to induce IL-17 production by γδ T cells and memory CD4 Th17 cells in the absence of T cell receptor involvement. IL-18 and IL-12 also synergize to induce IFN-γ production from memory T cells and NK cells, which promotes Th1 responses.
[0156] Furthermore, it is known that NLRP3 inflammasome activation can contribute to the onset and progression of various inflammasome-related diseases / disorders, immune diseases, inflammatory diseases, and autoimmune diseases. Additionally, NLRP3 inflammasome activation is associated with neuroinflammation-related disorders, e.g., brain infections, acute injuries, multiple sclerosis, Alzheimer's disease, and neurodegenerative diseases; cardiovascular / metabolic disorders / disorders, e.g., cardiovascular risk reduction (CvRR), atherosclerosis, type I and type II diabetes mellitus and related complications (e.g., nephropathy, retinopathy), peripheral artery disease (PAD), acute heart failure, and hypertension; wound healing and scar formation; and inflammatory skin diseases, e.g., acne, hidradenitis suppurativa, asthma, sarcoidosis, and age-related macular degeneration. It is known that it can also contribute to the development and progression of cancer-related diseases / disorders, such as myeloproliferative neoplasms, leukemia, myelodysplastic syndrome (MDS), myelofibrosis, lung cancer, and colon cancer.
[0157] In addition, JNK (c-Jun N-terminal kinase) and NF-κB (Nuclear Factor-κB) are signaling pathways that play an important role in neuroinflammatory responses. It is known that JNK induces intracellular inflammatory responses in response to various external stimuli, and that the activation of NF-κ contributes to further increasing inflammation by regulating the expression of inflammation-related genes.
[0158] As such, it was found that vandetanib of the present invention can inhibit the hyperactivation of microglia and astrocytes induced by LPS and the neuroinflammatory response induced thereby, and can inhibit and reduce LPS-mediated neuroinflammation by inhibiting the activity of major signaling pathways, NLRP3 / SOD2 and JNK / NK-κB.
[0159] In addition, the composition of the present invention containing vandetanib as an active ingredient has activity that inhibits apoptosis of nerve cells.
[0160] According to one embodiment of the present invention, it was investigated whether vandetanib could inhibit LPS-induced apoptosis of neurons, and as a result, it was confirmed that vandetanib could inhibit LPS-mediated pyroptosis. Meanwhile, it was found that vandetanib did not affect ferroptosis, another form of apoptosis.
[0161] Pyroptosis is a highly inflammatory form of programmed cell death that occurs most frequently when a cell is infected with an intracellular pathogen. The process of pyroptosis is initiated by the formation of a large supramolecular complex called an inflammasome (also called a pyroptosome) in response to intracellular danger signals. The inflammasome activates a different series of caspases compared to apoptosis, such as caspase-1 / 4 / 5 in humans and caspase-11 in mice. These caspases contribute to the maturation and activation of pro-inflammatory cytokines IL-1β and IL-18 and the pore-forming protein guardermin D, and when pores are formed, the cell membrane ruptures and various damage-associated molecular pattern (DAMP) molecules, such as HMGB-1, ATP, and DNA as well as cytokines, are released out of the cell. These molecules recruit more immune cells and prolong the inflammatory cascade of the tissue, ultimately inducing apoptosis.
[0162] It was found that vandetanib of the present invention has the activity of protecting neurons by inhibiting apoptosis caused by inflammatory response in brain cells, i.e., neurons.
[0163] Meanwhile, vandetanib of the present invention was shown not to affect ferroptosis. Ferroptosis is a reaction that occurs through the oxidation of lipids by iron within the cell; when lipids constituting the cell membrane phospholipids are oxidized, they cause toxicity to the cell, leading to cell death. Therefore, although ferroptosis is also a type of cell death, it possesses different biochemical characteristics from apoptosis and its mechanism of action is clearly distinct.
[0164] In the present invention, it was confirmed that the protective effect of vandetanib on neurons from apoptosis is achieved by inhibiting apoptosis caused by pyroptosis rather than ferroptosis.
[0165] Therefore, the present invention has shown that the drug vandetanib can prevent, improve, and treat brain developmental disorders or brain inflammatory diseases by inhibiting the production of LPS-induced pro-inflammatory cytokines, inhibiting LPS-mediated NLRP3 and SOD2 expression, inhibiting the activity of inflammation-related JNK and NK-κB signaling pathways, as well as inhibiting the activity of microglia or astrocytes and inhibiting neuronal apoptosis.
[0166] Accordingly, the present invention may provide a pharmaceutical composition for the prevention or treatment of brain developmental disorders or brain inflammatory diseases, comprising vandetanib or a pharmaceutically acceptable salt thereof as an active ingredient.
[0167] In the present invention, the vandetanib may be a compound represented by the following chemical formula 1, and may also be used in the form of a pharmaceutically acceptable salt thereof.
[0168] <Chemical Formula 1>
[0169]
[0170] In the present invention, the pharmaceutically acceptable salt may be an acid addition salt formed using an organic acid or an inorganic acid. The organic acid includes, for example, formic acid, acetic acid, propionic acid, lactic acid, butyric acid, isobutyric acid, trifluoroacetic acid, malic acid, maleic acid, malonic acid, fumaric acid, succinic acid, succinic acid monoamide, glutamic acid, tartaric acid, oxalic acid, citric acid, glycolic acid, glucuronic acid, ascorbic acid, benzoic acid, phthalic acid, salicylic acid, anthranilic acid, dichloroacetic acid, aminooxyacetic acid, benzenesulfonic acid, p-toluenesulfonic acid, and methanesulfonic acid salts; the inorganic acid includes, for example, hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, nitric acid, carbonic acid, and boric acid salts. The aforementioned acid addition salts may be prepared through methods known in the art.
[0171] The pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier in addition to the active ingredient. The composition including the pharmaceutically acceptable carrier may be in various formulations, oral or parenteral. When formulating, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
[0172] Solid dosage forms for oral administration include tablets, powders, granules, capsules, etc., and these solid dosage forms are prepared by mixing at least one excipient, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc., with one or more compounds. In addition, lubricants such as magnesium stearate and talc are also used in addition to simple excipients. Liquid dosage forms for oral administration include suspensions, liquid formulations, emulsions, syrups, etc., and may include various excipients, such as humectants, sweeteners, flavorings, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin.
[0173] Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspension solvents. Witepsol, macrogol, Tween 61, cocoa paste, laurin paste, glycerogelatin, etc. may be used as bases for suppositories.
[0174] The above pharmaceutical composition may have any one formulation selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, liquid formulations, emulsions, syrups, sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations, and suppositories.
[0175] In addition, as described above, the pharmaceutical composition of the present invention can be administered to treat brain developmental disorders or brain inflammatory diseases.
[0176] The composition of the present invention is administered in a pharmaceutically effective amount. The term "pharmaceutically effective amount" means an amount sufficient to treat a disease with a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level may be determined based on factors including individual type and severity, age, gender, drug activity, sensitivity to the drug, time of administration, route of administration and elimination rate, duration of treatment, concurrently used drugs, and other factors well known in the medical field.
[0177] The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered as a single or multiple doses. It is important to administer an amount that obtains maximum effect with a minimum amount without side effects, taking all of the above factors into consideration. The typical dosage of the pharmaceutical composition of the present invention is within the range of 0.001-100 mg / kg for adults.
[0178] The administration route of the above pharmaceutical composition may be any general route capable of reaching the target tissue. Depending on the purpose, the composition of the present invention may be administered intraperitoneally, intravenously, intramuscularly, subcutaneously, intradermally, orally, intranasally, intrapulmonaryly, or rectally, but is not limited thereto. Additionally, the composition may be administered by any device capable of delivering the active substance to target cells.
[0179] The composition of the present invention can be used alone or in combination with methods using surgery, hormone therapy, drug therapy, and biological response modulators for the prevention and treatment of brain developmental disorders or brain inflammatory diseases.
[0180] In addition, the brain inflammatory disease according to the present invention may be selected from the group consisting of multiple sclerosis, stroke, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, Creutzfeldt-Jakob disease, post-traumatic stress disorder, depression, schizophrenia, and amyotrophic lateral sclerosis, although this is not limited thereto.
[0181] It is known that inflammatory responses occurring in nerve cells can affect brain development, and in particular, inflammation during infancy or pregnancy can have a negative impact on brain cell development. Furthermore, severe inflammation is known to be a cause of brain developmental disorders such as Attention Deficit Hyperactivity Disorder (ADHD), schizophrenia, bipolar disorder, or autism spectrum disorder (ASD).
[0182] Therefore, the composition containing vandetanib of the present invention can prevent, improve, and treat brain developmental disorders.
[0183] The brain developmental disorders that the composition of the present invention can prevent, improve, and treat are not limited thereto, but may be selected from the group consisting of attention deficit hyperactivity disorder (ADHD), schizophrenia, bipolar disorder, and autism spectrum disorder (ASD).
[0184] Furthermore, the present invention may provide a health functional food for the prevention or improvement of brain developmental disorders or brain inflammatory diseases, comprising vandetanib or an acceptable salt thereof as an active ingredient.
[0185] The health functional food of the present invention can be easily utilized as a food effective in preventing and improving symptoms of brain developmental disorders or brain inflammatory diseases, for example, as a main ingredient, auxiliary ingredient, food additive, functional food, or beverage.
[0186] In this document, the term “food” refers to a natural product or processed product containing one or more nutrients, preferably one that has undergone a certain degree of processing to become ready for direct consumption, and includes, in the conventional sense, food, food additives, functional foods, and beverages.
[0187] Foods to which the composition for preventing and improving symptoms of brain developmental disorders or brain inflammatory diseases according to the present invention may be added include, for example, various types of food, beverages, chewing gum, tea, vitamin complexes, functional foods, etc. Additionally, in the present invention, food includes, but is not limited to, special nutritional foods (e.g., infant formula, baby food, etc.), processed meat products, fish products, tofu products, jelly products, noodles (e.g., ramen, noodles, etc.), bread products, health supplements, seasoning foods (e.g., soy sauce, soybean paste, red pepper paste, mixed sauce, etc.), sauces, confectionery products (e.g., snacks), candies, chocolates, chewing gum, ice cream, dairy products (e.g., fermented milk, cheese, etc.), other processed foods, kimchi, pickled foods (various types of kimchi, pickled vegetables, etc.), beverages (e.g., fruit beverages, vegetable beverages, soy milk, fermented beverages, etc.), and natural seasonings (e.g., ramen soup mix). The above food, beverage, or food additive can be manufactured by conventional manufacturing methods.
[0188] Furthermore, the term “functional food” refers to a group of foods to which added value has been imparted by using physical, biochemical, or biotechnological methods to enable the function of the food to act or manifest for a specific purpose, or refers to a food processed by designing it to sufficiently express in the body the in vivo regulatory functions regarding the regulation of biological defense rhythms, disease prevention, and recovery possessed by the food composition; specifically, it may be a health functional food. The functional food may include food science-acceptable food additives and may further include appropriate carriers, excipients, and diluents commonly used in the manufacture of functional foods.
[0189] Furthermore, in the present invention, the term “beverage” refers to a general term for something consumed to quench thirst or enjoy a taste, and includes functional beverages. The beverage contains the composition for the prevention and improvement of symptoms of brain developmental disorders or brain inflammatory diseases as an essential ingredient in the indicated proportions, and there are no special restrictions on other ingredients; it may contain various flavoring agents or natural carbohydrates, etc., as additional ingredients, just like conventional beverages.
[0190] Furthermore, in addition to what is described above, food containing the composition for preventing or improving brain developmental disorders or brain inflammatory diseases according to the present invention may contain various nutritional supplements, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, coloring agents and fillers (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc., and the above components may be used independently or in combination.
[0191] In a food containing a composition capable of preventing and improving symptoms of brain developmental disorders or brain inflammatory diseases according to the present invention, the amount of the composition according to the present invention may be included in an amount of 0.001% to 90% by weight of the total weight of the food, preferably in an amount of 0.1% to 40% by weight, and in the case of a beverage, in an amount of 0.001g to 2g, preferably 0.01g to 0.1g based on 100ml, but in the case of long-term consumption for the purpose of health and hygiene or health control, it may be less than the above range, and since the active ingredient has no problem in terms of safety, it may be used in an amount greater than the above range, so it is not limited to the above range.
[0192]
[0193] The present invention will be explained in more detail below through examples. These examples are merely for the purpose of explaining the present invention more specifically, and it will be obvious to those skilled in the art that the scope of the present invention is not limited to these examples.
[0194]
[0195] <Preparation and Experimental Methods>
[0196] Preparation of Vandetanib
[0197] Vandetanib, a VEGFR2 and EGFR inhibitor, was purchased from MedChemExpress (HY-10260, Monmouth Junction, NJ, USA). For in vitro assays, the dose of vandetanib used was 1 μM or 5 μM (DMSO solution), and for in vivo assays, it was 5 mg / kg (dissolved in 10% DMSO + 40% PEG + 5% Tween80 + 45% saline solution and administered intraperitoneally).
[0198]
[0199] Culture of BV2 microglia
[0200] BV2 microglia (Elabioscience Biotechnology Inc, Houston, TX, USA) were cultured in high-glucose DMEM (Dulbecco's Modified Eagle's Medium, Invitrogen, Carlsbad, CA, USA) supplemented with 5% fetal bovine serum (FBS, Invitrogen), 100 U / mL penicillin G, and 100 μg / mL streptomycin, and culture was performed in an environment maintained at 37°C and 5% CO2.
[0201]
[0202] MTT Assay
[0203] Experiments were conducted to analyze the cytotoxicity of vandetanib treatment on BV2 microglia. Specifically, BV2 microglia were seeded into 96-well plates at a density of 1 × 10⁴ cells per well and cultured in serum-free medium for 1 hour prior to drug treatment. Subsequently, BV2 microglia were treated with vandetanib (0.1, 1, 5, 10, or 20 μM) or vehicle (0.01, 0.05, 0.1, 0.25, or 0.5% DMSO) and cultured for 24 hours. Afterward, MTT solution was added and cultured for 2 hours, followed by the addition of DMSO to dissolve the formazan crystals. Then, after 20 minutes, the absorbance at 570 nm relative to 660 nm was measured using a SPECTROstar Nano microplate reader (BMG Labtech, Germany).
[0204]
[0205] Perform real-time quantitative PCR
[0206] To determine the effect of vandetanib on LPS-induced inflammatory responses in in vitro experiments, BV2 microglia and primary astrocytes were treated with vandetanib (1 μM or 5 μM) or vehicle (1% DMSO) for 30 minutes, then treated with LPS (1 μg / ml or 200 ng / ml) or PBS for 5.5 hours, and the mRNA levels of inflammatory cytokines (cox-2, tnf-α, il-1β, il-6) and inflammation-related target molecules (nlrp3, sod2, cdk4, cdk6) were analyzed by real-time quantitative PCR. In addition, in an in vivo experiment, wild-type mice were administered vandetanib (5 mg / kg, intraperitoneal administration) or vehicle (10% DMSO, 40% PEG, 5% Tween 80, physiological saline) daily for 2 weeks, followed by the administration of LPS (10 mg / kg, intraperitoneal injection) or PBS for 8 hours, and the mRNA levels of inflammatory cytokines (cox-2, tnf-α, il-1β, il-6), target molecules (nlrp3, sod2, cdk4, cdk6), glial cell activation markers (gbp2, tspo, gpnmb, cd44, cr3, cxcl10), and pyroptosis-related factors (nlrp6, asc, caspase-1, il-18, gsdmd, hmgb1) were analyzed by real-time quantitative PCR. For real-time PCR, cDNA was first synthesized using the Superscript cDNA Premix Kit II (GeNetBio), and the process was performed for 40 cycles on a QuantStudio™ 5 system (Thermo Fisher Scientific) using Fast SYBR Green Master Mix (Thermo Fisher Scientific, CA, USA). The GAPDH Ct value was used as the normalization value.Changes in mRNA levels (fold change) for the LPS-treated group and the vandetanib+LPS-treated group were calculated based on the control group (vehicle-treated group), and the primers used for real-time quantitative PCR are listed in Table 1 below.
[0207] 프라이머들GeneSequence (5' -> 3')nlrp3ForwardTCC ACA ATT CTG ACC CAC AAReverseACC TCA CAG AGG GTC ACC ACIl-1βForwardTTG ACG GAC CCC AAA AGA TGReverseAGG ACA GCC CAG GTC AAA GIba-1ForwardGGA CAG ACT GCC AGC CTA AGReverseGAC GGC AGA TCC TCA TCA TTcox-2ForwardCCACTTCAAGGGAGTCTGGReverseAGTCATCTGCTACGGGAGGAtnf-aForwardTCCAGGCGGTGCCTATGTReverseGCCCCTGCCACAAGCAcdk4ForwardCTGGAAATGCTGACCTTTAACCReverseGTGAACCTCGTAAGGAGAGGTGcdk6ForwardTCTCACAGAGTAGTGCATCGTReverseCGAGGTAAGGGCCATCTGAAAAsod2ForwardGGCCAAGGGAGATGTTACAAReverseGAACCTTTGGACTCCCACAcd44ForwardACTAGATCCCTCCGTTTCATCCReverseGGTTACATTCAAATCGATCTGCTGgbp2ForwardGGGGTCACTGTCTGACCACTReverseGGGAAACCTGGGATGAGATTcxcl10ForwardGCC GTC ATT TTC TGC CTC AReverseGCT TCC CTA TGG CCC TCA TTtspoForwardGCT GTG GAT CTT TCC AGA ACAReverseATG CCA AGA GGG TTT CTG Ccr3ForwardGCA GGA GTC GTA TGT GAG GReverseTTA CTG AGG TGG GGC GTC TgpnmbForwardCCAATTACGTGGCTGGTCTTReverseCCCAAATCATTCCTGCAGTTgapdhForwardTGT GTC CGT CGT GGA TCT GAReverseCCT GCTTCA CCA CCT TCT TGA
[0208] Primary astrocyte cell culture
[0209] The entire brains of 1-day-old (P1) C57BL / 6 mice were dissected and finely chopped using a 70 μm nylon mesh. Cell suspensions were obtained by culturing in a 5% CO2 incubator in low-glucose DMEM (1000 mg / L glucose) medium supplemented with 10% FBS, 100 units / mL penicillin, and 100 μg / mL streptomycin. Primary astrocytes were cultured at DIV 21 with shaking at 250 rpm for 8 hours at room temperature; subsequently, cells were detached using trypsin-EDTA and centrifuged at 1200 rpm for 3 minutes. The obtained primary astrocyte pellet was resuspended and dispensed into 12-well culture plates. For real-time PCR and nuclear fractionation, astrocytes (7.0 × 10⁶) 5 Cells / wells were sequentially treated with vandetanib (5 μM) or vehicle (1% DMSO) for 30 or 45 minutes, followed by treatment with LPS (200 ng / mL) or PBS for 5.5 hours.
[0210]
[0211] Preparation of Nucleus Fractionation
[0212] To analyze the effect of vandetanib on LPS-induced transcription factor expression in vitro, BV2 microglia and primary astrocytes were treated with 5 μM vandetanib or vehicle (1% DMSO) for 45 minutes. Subsequently, BV2 microglia were treated with LPS (1 μg / mL) or PBS, and primary astrocytes were treated with LPS (200 ng / mL) or PBS for 5.5 hours. After 6 hours, cytoplasmic fraction buffer (10 mM HEPES, pH 8.0, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 300 mM sucrose, 0.5 mM PMSF, and 0.1% NP-40) was added to the cells and incubated for 5 minutes, followed by centrifugation at 10,000 rpm for 1 minute at 4°C. Subsequently, the supernatant (cytoplasmic fraction) was obtained, and nuclear fraction buffer (10 mM HEPES, pH 8.0, 100 mM KCl, 100 mM NaCl, 0.2 mM EDTA, 0.5 mM DTT, 0.5 mM PMSF, 20% glycerol) was added to the pellet. After incubation on ice for 15 minutes, the pellet was centrifuged at 10,000 rpm for 15 minutes at 4°C. After centrifugation, the supernatant was obtained as the nuclear fraction and stored at -80°C until analysis.
[0213]
[0214] Western Blot
[0215] To determine whether vandetanib affects LPS-mediated downstream signaling in vitro, BV2 microglia were treated with vandetanib (5 μM) or vehicle (1% DMSO) for 45 minutes, followed by treatment with LPS (1 mg / ml) or PBS for 45 minutes. Subsequently, lysis buffer (50 mM Tris, pH 7.4, 1% Triton X-100, 2 mM CaCl2, 2 mM MgCl2), protease inhibitors, and phosphatase inhibitors (Bio-Rad Laboratories, Hercules, CA, USA) were added to the cells, and cell lysates were prepared by lysing on ice for 5 minutes. The cells were then centrifuged at 12,000 rpm for 15 minutes, and protein concentrations were measured using a protein analysis reagent (Bio-Rad Laboratories). For Western blot, 10 μg of protein was heated at 100°C for 5 minutes, loaded onto a 6% or 8% SDS-polyacrylamide gel for electrophoresis, and then transferred to a PVDF membrane (Millipore, Bedford, MA0, USA). The membrane was blocked with 5% skim milk dissolved in TBST or 5% BSA, treated with a primary antibody, and incubated overnight. The next day, the membrane was washed four times with TBST for 5 minutes each, and a peroxidase-conjugated secondary antibody was added and incubated at room temperature for 1 hour. Subsequently, the membrane was washed four times with TBST for 5 minutes each, and target proteins were detected using ECL Western blot detection reagent (GE Healthcare, Chicago, IL, USA). Image analysis was performed using Fusion Capt Advance software (Vilber Lourmat). In addition, the primary and secondary antibodies used in the Western blot are shown in Table 2 below.
[0216]
[0217] 항체들Primary antibodiesImmunogenHost speciesDilutionManufacturerCatalog no.ApplicationPCNAMouse1:1000Santa CruzSC-56WBp-JNKRabbit1:1000Cell Signaling9251WBJNKRabbit1:1000Cell Signaling9252WBp-NF-kBRabbit1:1000Cell Signaling3033WBNF-kBRabbit1:1000Cell Signaling8242WBGAPDHRabbit1:5000Proteintech10494-1-APWBSecondary antibodiesAntibodyDilutionManufacturerCatalog no.ApplicationGoat anti-rabbit, HRP1:5000EnzoADI-SAB-300-JWBGoat anti-mouse, HRP1:5000EnzoADI-SAB-100-JWB
[0218] In addition, to analyze the effect of vandetanib on LPS-induced inflammatory responses in vivo, wild-type (WT) mice were administered vandetanib (5 mg / kg, intraperitoneal) or vehicle (10% DMSO, 40% PEG, 5% Tween 80 in saline) daily for 14 days, and on the 14th day, vandetanib or vehicle was injected, followed by the administration of LPS (10 mg / kg, intraperitoneal) or PBS 30 minutes later. Subsequently, brain tissue, along with the cortex and hippocampus, was excised from each mouse group, homogenized with RIPA lysis buffer (Merck Millipore, Billerica, MA, USA) containing a 1% protease and phosphatase inhibitor cocktail (Thermo Scientific, Waltham, MA, USA), and then left on ice for 1 hour. The brain lysate was centrifuged at 20,000 g for 15 minutes at 4°C, and the supernatant was stored at -80°C until analysis. For Western blot, 10 μg of protein dissolved in Laemmli Sample Buffer (Cat. No. 161-0747; Bio-Rad) was loaded into each well of an 8% SDS-PAGE gel. The proteins separated by electrophoresis were transferred to a PVDF membrane (Millipore, Bedford, MA, USA), blocked with 5% skim milk or TBST containing 5% BSA, and the primary antibody was added and incubated overnight at 4°C. Subsequently, the membrane was incubated with a secondary antibody conjugated to horseradish peroxidase at room temperature for 1 hour. Then, an ECL solution (ATTO, Tokyo, Japan) was added, and images were acquired and analyzed using Fusion Capt Advance software (Vilber Lourmat, Eberhardzell, Germany).
[0219]
[0220] Wild mouse preparation
[0221] For animal experiments, male C57BL / 6 mice (3 months old, 24–26 g; Coatec, Gyeonggi-do, Korea) were randomly assigned to the experimental group. Mice were housed in pathogen-free cages at a density of 3–5 per cage, and were allowed unrestricted intake of food and water while maintaining a 12-hour light-dark cycle. All animal experiments were approved by the Institutional Biosafety Committee (IBC) and were conducted in compliance with the animal experiment guidelines of the Korea Brain Research Institute (KBRI, approval number IACUC-24-0004).
[0222]
[0223] Immunofluorescence staining (IF)
[0224] The following experiment was conducted to determine whether vandetanib affects the levels of LPS-induced inflammatory cytokine production in vivo. Wt. WT mice were randomly divided into three groups: a vehicle administration group, an LPS administration group, and a vandetanib and LPS administration group. Wt. WT mice were administered vandetanib (5 mg / kg, ip) or vehicle (a solution of 10% DMSO, 40% PEG, and 5% Tween 80 dissolved in physiological saline) intraperitoneally (ip) daily for 14 days. Thirty minutes after vandetanib administration, LPS (10 mg / kg, ip) or PBS was administered to the mice; eight hours later, the mice were perfused and fixed with 4% paraformaldehyde (Cembio, Seoul, Korea), after which the brains were dehydrated in 30% sucrose for 72 hours. The brain was sectioned into 30 μm thick slices in the coronal plane using a cryogenic storage device (Leica CM1850, Wetzlar, Germany). Brain tissue sections were blocked with 10% normal goat serum (Vector Laboratories, Burlingame, CA, USA) for 2 hours at room temperature and immunostained overnight at 4°C with the following primary antibodies: anti-Iba-1 (1:500, Wako, 019-19741, Richmond, VA, USA), anti-GFAP (1:500, Invitrogen, 13-0300, Waltham, MA, USA), anti-COX-2 (1:200, Abcam, ab15191, Cambridge, UK), anti-IL-1β (1:200, Abcam, ab9722, Cambridge, UK), anti-NLRP3 (1:200, Novus, NBP2-12446, Littleton, CO, USA), anti-TNF-α (1:200, Novus, NBP1-19532, St. Louis, MO, USA). SOD2(1:200, Cell Signaling, 13141, Massachusetts, USA).
[0225] Subsequently, brain tissue sections were washed three times with PBST buffer and treated with a secondary antibody conjugated to Alexa 594 or Alexa 488, and incubated at room temperature for 2 hours. After mounting on glass slides using Vectashield mounting solution containing DAPI (Vector Labs, Burlingame, CA), the immunostained tissues were imaged using a fluorescence microscope (DMi8, Leica Microsystems, Wetzlar, Germany) and analyzed using ImageJ (US National Institutes of Health, Bethesda, MD, USA). The primary and secondary antibodies used for immunofluorescence staining are shown in Table 3 below.
[0226]
[0227] Antibodies used for immunofluorescence stainingPrimary antibodiesImmunogenHost speciesDilutionManufacturerCatalog no.ApplicationTNF-aRabbit1:200NovusNBP1-19532IFCOX-2Rabbit1:200AbcamAB15191IFIba-1Rabbit1:500Wako019-19741I FGFAPRat1:500Invitrogen13-0300IFNLRP3Goat1:200AbcamAB4207IFIL-1bRabbit1:200AbcamAB9722IFSOD2Rabbit1:200cell signaling13141IFSecondary antibodiesAntibodyDilutionManufacturerCatalog no.ApplicationGoat anti-rabbit IgG, 5551:200InvitrogenA21428IFGoat anti-mouse IgG, 5551:200InvitrogenA21422IFGoat anti-mouse IgG, 4881:200InvitrogenA11001IFGoat anti-rat IgG, 4881:200InvitrogenA21434IFGoat anti-rabbit IgG, 4881:200InvitrogenA11008IF
[0228] Statistical processing
[0229] All data were analyzed using two-sided T-tests or ANOVA with GraphPad Prism 4 software. Post-hoc analysis was performed using Tukey's multiple comparison test with a significance level of p<0.05. Data were expressed as mean ± SEM (*p < 0.05, **p < 0.01, ***p < 0.001).
[0230] Data analysis was performed using GraphPad Prism 10 software (GraphPad Software, San Diego, CA, USA). Comparisons between experimental groups were analyzed using one-way ANOVA followed by Tukey's post hoc test. A p-value less than 0.05 was considered statistically significant, and results were expressed as mean ± standard deviation. Significance levels were indicated as *p < 0.05, **p < 0.01, and ***p < 0.001.
[0231]
[0232] Experimental Example 1: Vandetanib, which reduces the expression of LPS-induced inflammatory cytokines in BV2 microglia and primary microglia
[0233] Before confirming the anti-inflammatory effect of vandetanib, an EGFR and VEGFR2 inhibitor, the inventors evaluated the cytotoxicity of vandetanib in BV2 microglia by performing an MTT assay. The results showed that vandetanib did not exhibit cytotoxicity in BV2 microglia up to a maximum concentration of 10 μM (see Fig. 2). Next, BV2 microglia were treated with vehicle (1% DMSO) or vandetanib (1 or 5 μM) for 30 minutes, followed by treatment with LPS (200 ng / ml) or PBS, and the expression of inflammatory cytokines was analyzed via real-time PCR. As a result of the analysis, 5 μM vandetanib significantly inhibited the expression of LPS-induced Cox-2, Il-1β, Tnf-α, and IL-6 mRNA, whereas 1 μM vandetanib selectively inhibited the expression of LPS-induced Cox-2, Il-1β, Tnf-α, and IL-6 mRNA (see Figures 3 to 6).
[0234] Next, we investigated whether vandetanib, an EGFR and VEGFR2 inhibitor, could suppress the LPS-induced neuroinflammatory response in primary microglia. Primary microglia were treated with vehicle (1% DMSO) or vandetanib (5 μM) for 30 minutes, followed by treatment with LPS (200 ng / ml) or PBS for 5.5 hours, and real-time PCR was performed. As a result, it was confirmed that vandetanib treatment significantly reduced the mRNA levels of Cox-2, Il-1β, Tnf-α, and IL-6 induced by LPS (see Figures 7 to 10). These results demonstrate that vandetanib has an anti-inflammatory effect against LPS in both BV2 microglia and primary microglia.
[0235]
[0236] Experimental Example 2: Vandetanib alleviates LPS-induced activation and hypertrophy of microglia and astrocytes in wild-type mice
[0237] Next, the effect of vandetanib on the LPS-induced expression of its targets, VEGFR and EGFR, was investigated in vitro. Wild-type mice were injected daily with either vandetanib (5 mg / kg) or the vehicle (10% DMSO, 40% PEG, 5% Tween80, 45% saline) for 14 days, and on the 14th day, 30 minutes after the last injection, the mice were injected with LPS (10 mg / kg) or PBS. Eight hours after the last injection, the mice were sacrificed, and real-time PCR was performed. Experimental results confirmed that the expression of VEGFR2 and EGFR mRNA, targets of vandetanib, was significantly higher in the cortex and hippocampus of wild-type mice treated with LPS compared to wild-type mice treated with the vehicle (see Figures 11 and 12), and that treatment with vandetanib and LPS together significantly inhibited mRNA levels compared to treatment with LPS alone. This implies that vandetanib treatment can inhibit the expression of the targets VEGFR2 and EGFR in vivo.
[0238] Next, the inhibitory effects of vandetanib on LPS-mediated microglia activation, hypertrophy, and migration in wild-type mice were confirmed. When vandetanib was treated with LPS, it was observed that the Iba-1 fluorescence intensity and the area of the Iba-1 positive region in the cortex and hippocampus of wild-type mice decreased compared to when LPS was treated alone. On the other hand, the number of Iba-1 positive cells in the hippocampus and cortex did not change even when vandetanib and LPS were administered simultaneously (see Figs. 13 to 17).
[0239] Subsequently, it was determined whether treatment with vandetanib could downregulate LPS-induced astrogliosis and inflammatory cytokine levels in primary astrocytes in vivo. The experimental results confirmed that when treated with both vandetanib and LPS, the expression levels of Cox-2, Il-1β, Tnf-α, and Il-6 mRNA in primary astrocytes were reduced compared to treatment with LPS alone (see Figs. 18 to 21). Furthermore, when treated with both vandetanib and LPS, GFAP fluorescence intensity and GFAP positive area were significantly reduced in the hippocampus and cortex of wild-type mice (see Figs. 22 and 23), and the number of GFAP-positive cells decreased in the cortex, hippocampal CA1, CA3, and DG regions, but not in the hippocampal CA2 and CA4 regions (see Figs. 24 to 26). These results indicate that treatment with vandetanib inhibits LPS-induced activation and hypertrophy of microglia and astrocytes in wild-type mice, but has little effect on glial migration.
[0240]
[0241] Experimental Example 3: Vandetanib reducing the expression of inflammatory cytokines in wild-type mice
[0242] qPCR and immunofluorescence staining were performed on wild-type mice to determine whether treatment with vandetanib affects the levels of LPS-induced inflammatory cytokines in vivo. As a result, it was confirmed that the levels of Il-1b, Tnf-a, and Cox-2 mRNA in the cortex and hippocampus were significantly reduced when both vandetanib and LPS were administered compared to when LPS alone was administered (see Figs. 27 to 29). Additionally, immunofluorescence staining confirmed that the expression of IL-1b protein was reduced in the cortex and hippocampus when both vandetanib and LPS were administered compared to when LPS alone was administered (see Figs. 30 to 32). When both vandetanib and LPS were administered compared to when LPS alone was administered, TNF-α levels were significantly reduced in the cortex and hippocampal CA1, CA4, and DG regions, but not in the hippocampal CA2 and CA3 regions (see Figs. 33 to 35). Finally, when both vandetanib and LPS were administered, the expression of COX-2 protein in the cortex and hippocampus was significantly reduced compared to when LPS was administered alone (see Figs. 36 to 38), which means that vandetanib effectively inhibits the expression of LPS-induced IL-1β, TNF-α, and COX-2 in wild-type mice.
[0243]
[0244] Experimental Example 4: Vandetanib reducing microglia and astrocyte hyperactivity in wild-type mice
[0245] The inventors experimentally confirmed the effect of vandetanib treatment on the hyperactivation dynamics of microglia and astrocytes. To this end, qPCR was performed after treating wild-type mice with vandetanib. As a result, it was confirmed that administering both vandetanib and LPS significantly reduced the mRNA levels of Cxcl10 and Cd44 in the cortex and hippocampus of wild-type mice compared to administering LPS alone (see Figs. 39 and 40). However, even when both vandetanib and LPS were treated, the mRNA levels of Tspo and Gbp2 decreased only in the cortex (see Figs. 41 and 42), while the mRNA levels of gpnmb and cr3 remained unchanged (see Figs. 43 and 44). This indicates that vandetanib selectively regulates the hyperactivation dynamics of microglia and astrocytes induced by LPS in wild-type mice.
[0246]
[0247] Experimental Example 5: Vandetanib reducing JNK / P38 / c-Jun / STAT3 phosphorylation in BV2 microglia, primary astrocytes, and wild-type mice
[0248] Considering that JNK / P38-c-Jun-STAT3 signaling is involved in central and peripheral inflammatory responses, the inventors investigated the effects of vandetanib on JNK, P38, c-Jun, and STAT phosphorylation in vitro or in vivo. When evaluating whether treatment with vandetanib affects JNK phosphorylation in BV2 microglia, it was confirmed that JNK phosphorylation was reduced when both vandetanib and LPS were treated compared to when LPS was treated alone (see Figs. 45 to 47). Additionally, it was confirmed that in primary astrocytes, the phosphorylation of JNK and P38 was reduced when both vandetanib and LPS were administered compared to when LPS was administered alone (see Figs. 48 to 53).
[0249] In addition, the effect of vandetanib on the phosphorylation of transcription factors c-Jun / STAT3 was confirmed in vitro. It was found that when treated with both vandetanib and LPS, c-Jun phosphorylation was inhibited compared to when treated with LPS alone, but STAT3 phosphorylation was not (see Figs. 54 to 57). Similar to the in vitro results, c-Jun phosphorylation in the cortex and hippocampus of wild-type mice was significantly reduced when both vandetanib and LPS were administered (see Figs. 58 to 63), and it was confirmed that treatment with vandetanib and LPS inhibited STAT phosphorylation in the cortex and hippocampus without altering the total STAT3 levels (see Figs. 64 to 69).
[0250]
[0251] Experimental Example 6: Vandetanib alleviates LPS-mediated pytoptosis in wild-type mice
[0252] Since EGFR is involved in pyroptosis, a type of cell death associated with inflammation, the inventors confirmed through experiments whether vandetanib downregulated the expression of pyroptosis-related genes. As a result, the inventors confirmed that when both vandetanib and LPS were administered, the mRNA expression levels of pyroptosis markers Nlrp6, Asc, and Hmgb1 in the cortex and hippocampus of wild-type mice decreased compared to the administration of LPS alone (see Figs. 70 to 72). However, treatment with vandetanib and LPS did not affect the mRNA expression levels of Caspase-1, Gsdmd, and Il-18 in the cortex and hippocampus of wild-type mice (see Figs. 73 to 75). This implies that the administration of vandetanib can selectively suppress the expression of pyroptosis-related genes in wild-type mice.
[0253]
[0254] Experimental Example 7: Vandetanib inhibiting the expression of NLRP3 and SOD2 in vivo
[0255] To identify the molecular mechanism by which vandetanib treatment reduces in vivo neuroinflammatory responses, the mRNA and protein expression levels of NLRP3, a major neuroinflammation-related molecular target, were examined. Analysis using qPCR revealed that treatment with vandetanib and LPS significantly reduced Nlrp3 and Pro-il-1b mRNA levels in the cortex and hippocampus of wild-type mice compared to treatment with LPS alone (see Figures 76 and 77). Additionally, to determine whether vandetanib alters LPS-mediated NLRP3 expression levels in vitro, treatment of BV2 microglia with 1 or 5 μM vandetanib significantly reduced LPS-induced Nlrp3 mRNA expression levels (see Figure 78).
[0256] Western blot was performed to confirm changes in NLRP3 expression, and the results confirmed that the expression of NLRP3 protein decreased in BV2 microglia treated with vandetanib and LPS (see Figs. 79 and 80). In addition, the expression levels of NLRP3 and Pro-il-1b mRNA decreased in primary microglia and primary astrocytes treated with vandetanib and LPS (see Figs. 81 and 82).
[0257] To determine whether vandetanib modulates the inflammatory response through NLRP3 regulation, BV2 microglia were transformed with control siRNA or Nlrp3 siRNA (40 nM) for 41 hours, then treated with vandetanib (5 μM) or vehicle (1% DMSO) for 30 minutes, followed by treatment with LPS (200 ng / ml) or PBS for 5.5 hours. qPCR analysis revealed that in BV2 microglia transformed with Nlrp3 siRNA, Nlrp3 mRNA expression decreased by 63.18% compared to the control group (see Fig. 83), and the mRNA levels of Cox-2, Il-1β, and Tnf-α were significantly reduced (see Figs. 84 to 87).
[0258] The inventors investigated whether treatment with vandetanib affects the expression of SOD2, a molecular target associated with neuroinflammation, in vitro. Treatment with 1 μM or 5 μM of vandetanib and LPS inhibited the expression of Sod2 mRNA in BV2 microglia compared to treatment with LPS alone (see Fig. 88) and reduced the expression of Sod mRNA in wild-type mice (see Fig. 89). Immunofluorescence staining results confirmed that treatment with vandetanib and LPS significantly reduced SOD protein levels in the cortex and hippocampus of wild-type mice compared to treatment with LPS alone (see Figs. 90 to 95).
[0259] Subsequently, we investigated whether vandetanib affects the LPS-stimulated inflammatory response in BV2 microglia via SOD2. To this end, BV2 microglia were transformed with control siRNA or Sod2 siRNA (40 nM) for 41 hours, followed by administration of vandetanib (5 μM) or vehicle (1% DMSO) for 30 minutes, and then treatment with LPS (200 ng / ml) or PBS for 5.5 hours. Treatment with vandetanib and LPS significantly reduced the expression levels of Cox-2, Il-1β, Il-6, and Tnf-α mRNA in both BV2 microglia transformed with control siRNA and Sod2 siRNA (see Figures 96 to 98), which indicates that vandetanib regulates the inflammatory response in a manner independent of SOD2.
[0260]
[0261] Experimental Example 8: Preparation of Gpr139- / - mice, an ADHD-like animal model
[0262] Attention Deficit Hyperactivity Disorder (ADHD) is a representative neurodevelopmental disorder characterized by hyperactivity, impulsivity, and attention deficits, and dysfunction of GPR139 signaling is known to contribute to the pathophysiology of ADHD. To develop an ADHD-like animal model, the inventors produced Gpr139 KO mice using the CRISPR-Cas9 system and produced Gpr139+ / + homozygous mice and Gpr139- / - homozygous mice (F1) from wild-type mice by crossing them to produce Gpr139+ / - heterozygous mice (F2). Subsequently, Gpr139+ / + homozygous mice, Gpr139+ / - heterozygous mice, and Gpr139- / - homozygous mice were produced by crossing the F2 heterozygous mice with each other. As a result of performing qPCR to confirm the deletion of the Gpr139 gene in the brains of Gpr139- / - mice, it was confirmed that the expression levels of Gpr139 mRNA in the hippocampus, habenula, and medial prefrontal cortex of Gpr139- / - mice were reduced compared to Gpr139+ / + mice (see Fig. 99).
[0263]
[0264] Experimental Example 9: Vandetanib restoring hyperactivity symptoms in ADHD-like Gpr139- / - mice
[0265] To determine whether treatment with vandetanib improves various ADHD symptoms, 7-month-old Gpr139+ / + and Gpr139- / - mice were injected daily with either vandetanib (5 mg / kg) or vehicle (10% DMSO, 40% PEG, 5% Tween80, 45% saline) for 14 days. Subsequently, an elevated plus maze test was conducted to evaluate the effect of vandetanib on hyperactivity symptoms. The results showed that Gpr139- / - mice had increased travel distance on the open arm compared to Gpr139+ / + mice (see Fig. 100). However, there was no difference in travel distance on the closed arm between Gpr139+ / + mice and Gpr139- / - mice (see Fig. 101), which means that vandetanib treatment restored hyperactivity symptoms in ADHD-like Gpr139- / - mice.
[0266]
[0267] Experimental Example 10: Vandetanib improving cognitive memory and sociality in ADHD-like Gpr139- / - mice
[0268] To confirm the effect of vandetanib on attention in an ADHD-like mouse model, the inventors injected 7-month-old Gpr139+ / + mice and Gpr139- / - mice with vandetanib (5 mg / kg) or vehicle daily for 14 days. Subsequently, a novel object recognition test was performed to evaluate recognition memory. The inventors confirmed that Gpr139- / - mice showed reduced preference for novel objects compared to Gpr139+ / + mice, and specifically confirmed that administration of vandetanib increased preference for novel objects in Gpr139- / - mice but not in Gpr139+ / + mice (see Fig. 102).
[0269] Subsequently, we investigated whether vandetanib treatment affected sociality and social cognitive memory in an ADHD-like mouse model. A 3-chamber test was performed using 7-month-old Gpr139+ / + and Gpr139- / - mice. In both Gpr139- / - and Gpr139+ / + mice, the time taken to explore the mouse room was significantly increased compared to the empty room, and it was confirmed that vandetanib treatment enhanced the sociality index of Gpr139- / - mice (see Figures 103 and 104). This indicates that vandetanib improved the sociality of the ADHD-like mouse model.
[0270] Finally, when investigating the effects of vandetanib on social cognitive memory, Gpr139- / - mice had difficulty distinguishing between familiar mice and new mice. On the other hand, Gpr139- / - mice administered vandetanib successfully distinguished between familiar mice and unfamiliar mice (see Figures 105 and 106), and their social cognitive ability increased. These results indicate that treatment with vandetanib improved ADHD attention deficit symptoms and sociality in Gpr139- / - mice.
[0271] The present invention relates to a composition for the prevention or treatment of brain developmental disorders and brain inflammatory diseases comprising vandetanib as an active ingredient.
Claims
1. A compound comprising vandetanib or a pharmaceutically acceptable salt thereof as an active ingredient, A pharmaceutical composition for the prevention or treatment of brain developmental disorders or brain inflammatory diseases.
2. In Paragraph 1, The above composition is, Inhibition of production of pro-inflammatory cytokines; Inhibition of NLRP3 and SOD2 expression; Inhibition of the activity of JNK and NK-κ signaling pathways; or A pharmaceutical composition for the prevention or treatment of brain developmental disorders or brain inflammatory diseases, characterized by having the effect of inhibiting the activity of microglia or astrocytes.
3. In Paragraph 1, The above composition is a pharmaceutical composition for the prevention or treatment of brain developmental disorders or brain inflammatory diseases, characterized by inhibiting apoptosis of nerve cells.
4. In Paragraph 3, A pharmaceutical composition for the prevention or treatment of brain developmental disorders or brain inflammatory diseases, characterized by inhibiting apoptosis.
5. In Paragraph 1, The above composition is a pharmaceutical composition for the prevention or treatment of brain developmental disorders or brain inflammatory diseases, characterized by inhibiting an inflammatory response within nerve cells.
6. In Paragraph 5, A pharmaceutical composition for the prevention or treatment of brain developmental disorders or brain inflammatory diseases, characterized in that the inflammation is induced by LPS (Lipopolysaccharide).
7. In Paragraph 2, A pharmaceutical composition for the prevention or treatment of brain developmental disorders or brain inflammatory diseases, characterized in that the above-mentioned pro-inflammatory cytokine is IL-1β, IL-6, COX-2, or TNF-α.
8. In Paragraph 1, A pharmaceutical composition for the prevention or treatment of brain developmental disorders or brain inflammatory diseases, characterized in that the brain developmental disorder is selected from the group consisting of attention deficit hyperactivity disorder (ADHD), schizophrenia, bipolar disorder, and autism spectrum disorder (ASD).
9. In Paragraph 1, A pharmaceutical composition for the prevention or treatment of brain developmental disorders or brain inflammatory diseases, characterized in that the brain inflammatory disease is selected from the group consisting of multiple sclerosis, stroke, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, Creutzfeldt-Jakob disease, post-traumatic stress disorder, depression, schizophrenia, and amyotrophic lateral sclerosis.
10. A food composition for the prevention or improvement of brain developmental disorders or brain inflammatory diseases, comprising vandetanib or a salt thereof as an active ingredient.
11. In Paragraph 10, The above composition is, Inhibition of production of pro-inflammatory cytokines; Inhibition of NLRP3 and SOD2 expression; Inhibition of the activity of JNK and NK-κB signaling pathways; or A food composition for the prevention or improvement of brain developmental disorders or brain inflammatory diseases, characterized by having the effect of inhibiting the activity of microglia or astrocytes.
12. In Paragraph 10, The above composition is a food composition for the prevention or improvement of brain developmental disorders or brain inflammatory diseases, characterized by inhibiting pyroptosis of nerve cells.
13. In Paragraph 10, The above composition is a food composition for the prevention or improvement of brain developmental disorders or brain inflammatory diseases, characterized by inhibiting an inflammatory response induced by LPS (Lipopolysaccharide).
14. In Paragraph 10, A food composition for the prevention or improvement of brain developmental disorders or brain inflammatory diseases, characterized in that the above-mentioned brain developmental disorder is selected from the group consisting of attention deficit hyperactivity disorder (ADHD), schizophrenia, bipolar disorder, and autism spectrum disorder (ASD).
15. In Paragraph 10, A food composition for the prevention or improvement of brain developmental disorders or brain inflammatory diseases, characterized in that the above-mentioned brain inflammatory disease is selected from the group consisting of multiple sclerosis, stroke, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), Huntington's disease, Creutzfeldt-Jakob disease, post-traumatic stress disorder, depression, schizophrenia, and amyotrophic lateral sclerosis.
